sur Ondine Biomedical Inc (LON:OBIMF)
Ondine Biomedical Inc. Launches Steriwave Pilot at King's College Hospital
Ondine Biomedical Inc., a Canadian company known for light-activated antimicrobial treatments, has announced an upcoming pilot of its Steriwave technology at King's College Hospital (KCH) in London. KCH plans to incorporate Steriwave into a quality improvement initiative aimed at reducing hospital-acquired infections. The pilot is set to commence later this year.
Steriwave is a novel treatment that utilizes a light-activated agent to eradicate infection-causing pathogens effectively. Applied via nasal swab followed by red light laser activation, the treatment promises pathogen destruction without resistance development, presenting an alternative to antibiotics.
Previously, Steriwave was adopted by Mid Yorkshire Teaching NHS Trust and added to the NHS Supply Chain, enhancing accessibility across England and Wales.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Ondine Biomedical Inc